Chandrasekhara Reddy Chintakuntla

Title: Innovations of Chandrasekhara Reddy Chintakuntla

Introduction

Chandrasekhara Reddy Chintakuntla is a notable inventor based in Bengaluru, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target mutated forms of the epidermal growth factor receptor (EGFR). His work has the potential to impact the treatment of various cancers.

Latest Patents

Chintakuntla holds two patents related to 2-(2,4,5-substituted-anilino)pyrimidine compounds. These compounds and their pharmaceutically acceptable salts are designed to treat or prevent diseases mediated by specific mutated forms of EGFR, such as the L858R activating mutant, the Exon19 deletion activating mutant, and the T790M resistance mutant. The inventions also encompass pharmaceutical compositions that include these compounds, especially useful polymorphic forms, intermediates for manufacturing, and methods for treating diseases associated with different forms of EGFR.

Career Highlights

Throughout his career, Chintakuntla has worked with prominent companies in the pharmaceutical industry, including AstraZeneca AB. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Chintakuntla has collaborated with notable professionals in his field, including Sam Butterworth and Maurice Raymond Verschoyle Finlay. These collaborations have likely enriched his research and development efforts.

Conclusion

Chandrasekhara Reddy Chintakuntla is a distinguished inventor whose work in developing targeted cancer therapies showcases his commitment to advancing medical science. His contributions are poised to make a significant difference in the treatment of cancer patients.